The steroid catabolic pathway of the intracellular pathogen rhodococcus equi is important for pathogenesis and a target for vaccine development

PLoS Pathogens

Volumn 7, Issue 8, 2011, Pages

  van der Geize, R ^a   Grommen, A W F ^b   Hessels, G I ^a   Jacobs, A A C ^b   Dijkhuizen, L ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b INTERVET INTERNATIONAL BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5ALPHA HYDROXY METHYLHEXAHYDRO 1 INDANONE PROPIONATE; ANDROSTENEDIONE; BACTERIAL VACCINE; INDANONE DERIVATIVE; RHODOCOCCUS EQUI VACCINE; UNCLASSIFIED DRUG; CHOLESTEROL; LIVE VACCINE;

ACTINOMYCETALES INFECTION; ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GENE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CATABOLISM; CONTROLLED STUDY; FOAL; GENE CLUSTER; GENE IDENTIFICATION; GENE INACTIVATION; IMMUNOGENICITY; MACROPHAGE; NONHUMAN; PHENOTYPE; RHODOCOCCUS EQUI; RHODOCOCCUS EQUI INFECTION; SIGNAL TRANSDUCTION; STEROID CATABOLISM; STEROID METABOLISM; VACCINATION; ANIMAL; ANIMAL DISEASE; BACTERIAL PNEUMONIA; BIOLOGY; BIOSYNTHESIS; CELL LINE; GENETICS; HORSE; HORSE DISEASE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MOLECULAR CLONING; MULTIGENE FAMILY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; VIRULENCE;

ACTINOBACTERIA; ANIMALIA; MYCOBACTERIUM TUBERCULOSIS; RHODOCOCCUS EQUI;

ACTINOMYCETALES INFECTIONS; ADMINISTRATION, ORAL; ANIMALS; BACTERIAL VACCINES; CELL LINE; CHOLESTEROL; CLONING, MOLECULAR; COMPUTATIONAL BIOLOGY; GENES, BACTERIAL; HORSE DISEASES; HORSES; HUMANS; MACROPHAGES; MULTIGENE FAMILY; PNEUMONIA, BACTERIAL; RHODOCOCCUS EQUI; VACCINES, ATTENUATED; VIRULENCE;

EID: 80052330722     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002181     Document Type: Article

References (67)

1. Prescott JF, (1991) Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev 4: 20-34.
2. Mosser DM, Hondalus MK, (1996) Rhodococcus equi: an emerging opportunistic pathogen. Trends Microbiol 4: 29-33.
3. Yamshchikov AV, Schuetz A, Lyon GM, (2010) Rhodococcus equi infection. Lancet Infect Dis 10: 350-359.
4. Hondalus MK, Mosser DM, (1994) Survival and replication of Rhodococcus equi in macrophages. Infect Immun 62: 4167-4175.
5. Hondalus MK, (1997) Pathogenesis and virulence of Rhodococcus equi. Vet Microbiol 56: 257-268.
6. Meijer WG, Prescott JF, (2004) Rhodococcus equi. Vet Res 35: 383-396.
7. von Bargen K, Haas A, (2009) Molecular and infection biology of the horse pathogen Rhodococcus equi. FEMS Microbiol Rev 33: 870-891.
8. Giguère S, Prescott JF, (1997) Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals. Vet Microbiol 56: 313-334.
9. Takai S, Sekizaki T, Ozawa T, Sugawara T, Watanabe Y, et al. (1991) Association between a large plasmid and 15- to 17-kilodalton antigens in virulent Rhodococcus equi. Infect Immun 59: 4056-4060.
10. Takai S, Hines SA, Sekizaki T, Nicholson VM, Alperin DA, et al. (2000) DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC33701 and 103. Infect Immun 68: 6840-6847.
11. Giguere S, Hondalus MK, Yager JA, Darrah P, Mosser DM, et al. (1999) Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi. Infect Immun 67: 3548-3557.
12. Jain S, Bloom BR, Hondalus MK, (2003) Deletion of vapA encoding Virulence Associated Protein A attenuates the intracellular actinomycete Rhodococcus equi. Mol Microbiol 50: 115-128.
13. Letek M, Ocampo-Sosa AA, Sanders M, Fogarty U, Buckley T, et al. (2008) Evolution of the Rhodococcus equi vap pathogenicity island seen through comparison of host-associated vapA and vapB virulence plasmids. J Bacteriol 190: 5797-5805.
14. Tkachuk-Saad O, Prescott JF, (1991) Rhodococcus equi plasmids: isolation and partial characterization. J Clin Microbiol 29: 2696-2700.
15. Majno G, Joris I, (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146: 3-15.
16. Lührmann A, Mauder N, Sydor T, Fernandez-Mora E, Schulze-Luehrmann J, et al. (2004) Necrotic death of Rhodococcus equi-infected macrophages is regulated by virulence-associated plasmids. Infect Immun 72: 853-862.
17. von Bargen K, Polidori M, Becken U, Huth G, Prescott JF, et al. (2009) Rhodococcus equi virulence-associated protein A is required for diversion of phagosome biogenesis but not for cytotoxicity. Infect Immun 77: 5676-5681.
18. Coulson GB, Agarwal S, Hondalus MK, (2010) Characterization of the role of the pathogenicity island and vapG in the virulence of the intracellular actinomycete pathogen Rhodococcus equi. Infect Immun 78: 3323-3334.
19. Oliveira AF, Ferraz LC, Brocchi M, Roque-Barreira MC, (2007) Oral administration of a live attenuated Salmonella vaccine strain expressing the VapA protein induces protection against infection by Rhodococcus equi. Microbes Infect 9: 382-390.
20. Oliveira AF, Ruas LP, Cardoso SA, Soares SG, Roque-Barreira MC, (2010) Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection. PLoS One 5: e8644.
21. Haghighi HR, Prescott JF, (2005) Assessment in mice of vapA-DNA vaccination against Rhodococcus equi infection. Vet Immunol Immunopathol 104: 215-225.
22. Phumoonna T, Barton MD, Vanniasinkam T, Heuzenroeder MW, (2008) Chimeric vapA/groEL2 DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice. Vaccine 26: 2457-2465.
23. Ashour J, Hondalus MK, (2003) Phenotypic mutants of the intracellular actinomycete Rhodococcus equi created by in vivo Himar1 transposon mutagenesis. J Bacteriol 185: 2644-2652.
24. Lopez AM, Townsend HG, Allen AL, Hondalus MK, (2008) Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi. Vaccine 26: 998-1009.
25. Navas J, González-Zorn B, Ladrón N, Garrido P, Vázquez-Boland JA, (2001) Identification and mutagenesis by allelic exchange of choE, encoding a cholesterol oxidase from the intracellular pathogen Rhodococcus equi. J Bacteriol 183: 4796-4805.
26. Pei Y, Dupont C, SydorT, HaasA, Prescott JF, (2006) Cholesterol oxidase (ChoE) is not important in the virulence of Rhodococcus equi. Vet Microbiol 118: 240-246.
27. Pei Y, Nicholson V, Woods K, Prescott JF, (2007) Immunization by intrabronchial administration to 1-week-old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103+. Vet Microbiol 125: 100-110.
28. Wall DM, Duffy PS, Dupont C, Prescott JF, Meijer WG, (2005) Isocitrate lyase activity is required for virulence of the intracellular pathogen Rhodococcus equi. Infect Immun 73: 6736-6741.
29. Pei Y, Parreira V, Nicholson VM, Prescott JF, (2007) Mutation and virulence assessment of chromosomal genes of Rhodococcus equi 103. Can J Vet Res 71: 1-7.
30. He H, Zahrt TC, (2005) Identification and characterization of a regulatory sequence recognized by Mycobacterium tuberculosis persistence regulator MprA. J Bacteriol 187: 202-212.
31. MacArthur I, Parreira VR, Lepp D, Mutharia LM, Vazquez-Boland JA, et al. (2011) The sensor kinase MprB is required for Rhodococcus equi virulence. Vet Microbiol In press.
32. Ahmad S, Roy PK, Basu SK, Johri BN, (1993) Cholesterol side-chain cleavage by immobilized cells of Rhodococcus equi DSM89-133. Indian J Exp Biol 31: 319-322.
33. Murohisa T, Iida M, (1993) Some new intermediates in microbial side chain degradation of β-sitosterol. J Ferment Bioeng 76: 174-177.
34. Van der Geize R, de Jong W, Hessels GI, Grommen AW, Jacobs AA, et al. (2008) A novel method to generate unmarked gene deletions in the intracellular pathogen Rhodococcus equi using 5-fluorocytosine conditional lethality. Nucleic Acids Res 36: e151.
35. Lee SS, Sih CJ, (1967) Mechanisms of steroid oxidation by microorganisms. XII. Metabolism of hexahydroindanpropionic acid derivatives. Biochemistry 6: 1395-1403.
36. Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, et al. (2007) A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci USA 104: 1947-1952.
37. Pandey AK, Sassetti CM, (2008) Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 105: 4376-4380.
38. Yam KC, D'Angelo I, Kalscheuer R, Zhu H, Wang JX, et al. (2009) Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog 5: e1000344.
39. Hu Y, van der Geize R, Besra GS, Gurcha SS, Liu A, et al. (2010) 3-Ketosteroid 9alpha-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis. Mol Microbiol 75: 107-121.
40. Mohn WW, van der Geize R, Stewart GR, Okamoto S, Liu J, et al. (2008) The actinobacterial mce4 locus encodes a steroid transporter. J Biol Chem 283: 35368-35374.
41. Rengarajan J, Bloom BR, Rubin EJ, (2005) Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci USA 102: 8327-8332.
42. Letek M, González P, Macarthur I, Rodríguez H, Freeman TC, et al. (2010) The genome of a pathogenic Rhodococcus: cooptive virulence underpinned by key gene acquisitions. PLoS Genet 6: e1001145.
43. Finn RD, Mistry J, Tate J, Coggill P, Heger A, et al. (2010) The Pfam protein families database. Nucleic Acids Res Database Issue 38: D211-222.
44. Horinouchi M, Yamamoto T, Taguchi K, Arai H, Kudo T, (2001) Meta-cleavage enzyme tesB is necessary for testosterone degradation in Comamonas testosteroni TA441. Microbiology (UK) 147: 3367-3375.
45. Horinouchi M, Hayashi T, Koshino H, Kurita T, Kudo T, (2005) Identification of 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oic acid, 4-hydroxy-2-oxohexanoic acid, and 2-hydroxyhexa-2,4-dienoic acid and related enzymes involved in testosterone degradation in Comamonas testosteroni TA441. Appl Environ Microbiol 71: 5275-5281.
46. Miclo A, Germain P, (1990) Catabolism of methylperhydroindanedione propionate by Rhodococcus equi: evidence of a MEPHIP-reductase activity. Appl Microbiol Biotechnol 32: 594-599.
47. Miclo A, Germain P, (1992) Hexahydroindanone derivatives of steroids formed by a Rhodococcus equi. Appl Microbiol Biotechnol 36: 456-460.
48. Van der Geize R, Hessels GI, van Gerwen R, van der Meijden P, Dijkhuizen L, (2002) Molecular and functional characterization of kshA and kshB, encoding two components of 3-ketosteroid 9α-hydroxylase, a class IA monooxygenase, in Rhodococcus erythropolis strain SQ1. Mol Microbiol 45: 1007-1018.
49. Loria RM, (2009) Beta-androstenes and resistance to viral and bacterial infections. Neuroimmunomodulation 16: 88-95.
50. Kendall SL, Burgess P, Balhana R, Withers M, Ten Bokum A, et al. (2010) Cholesterol utilization in mycobacteria is controlled by two TetR-type transcriptional regulators: kstR and kstR2. Microbiology 156: 1362-1371.
51. Chirino-Trejo JM, Prescott JF, (1987) Antibody response of horses to Rhodococcus equi antigens. Can J Vet Res 51: 301-305.
52. Takai S, Shoda M, Sasaki Y, Tsubaki S, Fortier G, et al. (1999) Restriction fragment length polymorphisms of virulence plasmids in Rhodococcus equi. J Clin Microbiol. 37: 3417-3420.
53. Hooper-McGrevy KE, Wilkie BN, Prescott JF, (2005) Virulence-associated protein-specific serum immunoglobulin G-isotype expression in young foals protected against Rhodococcus equi pneumonia by oral immunization with virulent R. equi. Vaccine 23: 5760-5767.
54. Martens RJ, Martens JG, Fiske RA, Hietala SK, (1989) Rhodococcus equi foal pneumonia: protective effects of immune plasma in experimentally infected foals. Equine Vet J 21: 249-255.
55. Madigan JE, Hietala S, Muller N, (1991) Protection against naturally acquired Rhodococcus equi pneumonia in foals by administration of hyperimmune plasma. J Reprod Fertil (Suppl 44): 571-578.
56. Hines SA, Kanaly ST, Byrne BA, Palmer GH, (1997) Immunity to Rhodococcus equi. Vet Microbiol 56: 177-185.
57. Hurley JR, Begg AP, (1995) Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals. Aust Vet J 72: 418-420.
58. Giguère S, Gaskin JM, Miller C, Bowman JL, (2002) Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals. J Am Vet Med Assoc 220: 59-63.
59. Dawson TR, Horohov DW, Meijer WG, Muscatello G, (2010) Current understanding of the equine immune response to Rhodococcus equi. An immunological review of R. equi pneumonia. Vet Immunol Immunopathol 135: 1-11.
60. Weinstock DM, Brown AE, (2002) Rhodococcus equi: an emerging pathogen. Clin Infect Dis 34: 1379-1385.
61. Roda RH, Young M, Timpone J, Rosen J, (2009) Rhodococcus equi pulmonary-central nervous system syndrome: brain abscess in a patient on high-dose steroids-a case report and review of the literature. Diagn Microbiol Infect Dis 63: 96-99.
62. Kedlaya I, Ing MB, Wong SS, (2001) Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin Infect Dis 32: e39-e46.
63. De la Pena-Moctezuma A, Prescott JF, (1995) Association with HeLa cells by Rhodococcus equi with and without the virulence plasmid. Vet Microbiol 46: 383-392.
64. Benoit S, Benachour A, Taouji S, Auffray Y, Hartke A, (2001) Induction of vap genes encoded by the virulence plasmid of Rhodococcus equi during acid tolerance response. Res Microbiol 152: 439-449.
65. Vishniac W, Santer M, (1957) The thiobacilli. Bacteriol Rev 21: 195-213.
66. Sundstrom C, Nilsson K, (1976) Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer 17: 565-577.
67. Verbeke G, Molenberghs G, (2000) Linear mixed models for longitudinal data. New York Springer-Verlag.